Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

Cited by (480)

Items 201–300 of 480

1. NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir.
   Si-Min Zhang, D. Rehling, A. Jemth, Adam Throup, N. Landázuri, I. Almlöf, M. Göttmann, N. Valerie, Sanjay R. Borhade, P. Wakchaure et al. · 2021 · Cell Chemical Biology
2. Better prediction of the local concentration–effect relationship: the role of physiologically based pharmacokinetics and quantitative systems pharmacology and toxicology in the evolution of model-informed drug discovery and development
   Sebastian Polak, Zofia Tylutki, Mark Holbrook, Barbara Wiśniowska · 2019 · Drug Discovery Today
3. Mechanism for distribution of acotiamide, a novel gastroprokinetic agent for the treatment of functional dyspepsia, in rat stomach.
   K. Yoshii, M. Hirayama, Toshifumi Nakamura, Ryoko Toda, J. Hasegawa, M. Takei, Y. Mera, Yoshihiro Kawabata · 2011 · Journal of Pharmacy and Science
4. Pharmacokinetics and metabolism of the reactive oxygen scavenger alpha-phenyl-N-tert-butylnitrone in the male Sprague-Dawley rat.
   Mary E. Trudeau-Lame, A. Kalgutkar, M. Lafontaine · 2003 · Drug Metabolism And Disposition
5. The influence of binding to albumin and α1-acid glycoprotein on the clearance of drugs by the liver
   D. Meijer, P. van der Sluijs · 1987 · Pharmaceutisch Weekblad
6. Protein binding and hepatic clearance: Studies with tolbutamide, a drug of low intrinsic clearance, in the isolated perfused rat liver preparation
   W. Schary, M. Rowland · 1983 · Journal of pharmacokinetics and biopharmaceutics
7. Hemodynamic influences upon the variance of disposition residence time distribution of drugs
   M. Weiss · 1983 · Journal of pharmacokinetics and biopharmaceutics
8. Influence of renal failure on the hepatic clearance of bufuralol in man
   L. Balant, R. Francis, T. Tozer, A. Marmy, J. Tschopp, J. Fabre · 1980 · Journal of pharmacokinetics and biopharmaceutics
9. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data
   Riede, Julia, Poller, Birk, Umehara, Ken-ichi, Huwyler, Jörg, Camenisch, Gian · 2016 · European Journal of Pharmaceutical Sciences
10. Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
    Stefan Willmann, Matthias Frei, Gabriele Sutter, Katrin Coboeken, Thomas Wendl, Thomas Eißing, Jörg Lippert, Heino Staß · 2019 · CPT Pharmacometrics & Systems Pharmacology
11. Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis
    J. Bulitta, Yuanyuan Jiao, Stefanie K. Drescher, A. Oliver, A. Louie, B. Moyá, Xun Tao, M. Wittau, B. Tsuji, A. Zavascki et al. · 2018 · Clinical Pharmacokinetics
12. Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor
    Bernd Kammerer, Holger Scheible, Wolfgang Albrecht, Christoph H. Gleiter, Stefan Laufer · 2007 · Drug Metabolism and Disposition
13. Influence of plasma protein binding kinetics on hepatic clearance assessed from a “tube” model and a “well-stirred” model
    J. Jansen · 1981 · Journal of pharmacokinetics and biopharmaceutics
14. Metabolic Stability of D-Allulose in Biorelevant Media and Hepatocytes: Comparison with Fructose and Erythritol
    H. Maeng, Jin-Ha Yoon, Kwang-Hoon Chun, Sung Tae Kim, Dong-Jin Jang, Jieun Park, Yang Hee Kim, Seong-Bo Kim, Y. Kim · 2019 · Foods
15. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds
    Yejin Esther Yun, Andrea N. Edginton · 2019 · Journal of Toxicology and Environmental Health
16. Utility of Chimeric Mice with Humanized Liver for Predicting Human Pharmacokinetics in Drug Discovery: Comparison with in Vitro–in Vivo Extrapolation and Allometric Scaling
    Yoichi Naritomi, Seigo Sanoh, Shigeru Ohta · 2019 · Biological and Pharmaceutical Bulletin
17. Determination of species-difference in microsomal metabolism of amitriptyline using a predictive MRM-IDA-EPI method.
    Ji-Yoon Lee, Sang Yoon Lee, Kiho Lee, S. Oh, S. K. Kim · 2015 · Chemico-Biological Interactions
18. On the prediction of hepatic clearance using the diluted plasma in metabolic stability assay.
    Leonid M. Berezhkovskiy, S. C. Khojasteh, Jason S. Halladay, C. Hop · 2009 · Journal of Pharmacy and Science
19. Interspecies Scaling of Cimetidine–Theophylline Pharmacokinetic Interaction: Interspecies Scaling in Pharmacokinetic Interactions
    A. Gascón, B. Calvo, R. Hernández, A. Domínguez-Gil, J. Pedraz · 1994 · Pharmaceutical Research
20. In Vitro Techniques to Study Drug–Drug Interactions of Drug Metabolism: Cytochrome P450
    James Brian. Houston, Aleksandra Galetin · 2009 · Springer eBooks
21. Consideration of Fractional Distribution Parameter fd in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods
    Yoo-Seong Jeong, W. Jusko · 2022 · Pharmaceutical Research
22. Semimechanistic Population Pharmacokinetic Model to Predict the Drug–Drug Interaction Between S‐ketamine and Ticlopidine in Healthy Human Volunteers
    Muhammad W. Ashraf, M. Peltoniemi, K. Olkkola, P. Neuvonen, T. Saari · 2018 · CPT: Pharmacometrics & Systems Pharmacology
23. Toward an integrated human clearance prediction strategy that minimizes animal use
    Kevin C. Beaumont, Iain B. Gardner, Kathryn L. Chapman, Michael Hall, Malcolm Rowland · 2011 · Journal of Pharmaceutical Sciences
24. Some features of the kinetics and equilibrium of drug binding to plasma proteins
    Leonid M. Berezhkovskiy · 2008 · Expert Opinion on Drug Metabolism & Toxicology
25. NONLINEAR PHARMACOKINETICS OF PROPAFENONE IN RATS AND HUMANS: APPLICATION OF A SUBSTRATE DEPLETION ASSAY USING HEPATOCYTES FOR ASSESSMENT OF NONLINEARITY
    H. Komura, M. Iwaki · 2005 · Drug Metabolism And Disposition
26. Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model.
    Jun-ichi Yokoe, N. Iwasaki, Shunji Haruta, K. Kadono, K. Ogawara, K. Higaki, Toshikiro Kimura · 2003 · Journal of Controlled Release
27. Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure—Pharmacokinetic relationships
    N. Watari, Y. Sugiyama, N. Kaneniwa, Mitsuru Hiura · 1988 · Journal of pharmacokinetics and biopharmaceutics
28. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fup/fumic) for refined prediction of phase I mediated metabolic hepatic clearance
    Sujal V. Deshmukh, Andreas Harsch · 2010 · Journal of Pharmacological and Toxicological Methods
29. Introducing the Dynamic Well-Stirred Model for Predicting Hepatic Clearance and Extraction Ratio
    Zhengyin Yan, Li Ma, Pasquale Carione, Julie Huang, Nicky Hwang, Jane R. Kenny, Cornelis E. C. A. Hop · 2024 · Journal of Pharmaceutical Sciences
30. Assessing Liver-to-Plasma Partition Coefficients and In Silico Calculation Methods: When Does the Hepatic Model Matter in PBPK?
    Xiao‐Nan Li, William J. Jusko · 2022 · Drug Metabolism and Disposition
31. Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women
    Olaf Panknin, Andrea Wagenfeld, Wilhelm Bone, Eckhard Bender, Katrin Nowak‐Reppel, Amaury E. Fernández‐Montalván, Reinhard Nubbemeyer, Stefan Bäurle, Sven Ring, Norbert Schmees et al. · 2020 · Journal of Medicinal Chemistry
32. Comparison of In Vitro to In Vivo Extrapolation Approaches for Predicting Transporter-Mediated Hepatic Uptake Clearance Using Suspended Rat Hepatocytes
    Na Li, Akshay Badrinarayanan, Xingwen Li, John Roberts, Mike Hayashi, Manpreet Virk, Anshul Gupta · 2020 · Drug Metabolism and Disposition
33. The prediction of human response to ONO‐4641, a sphingosine 1‐phosphate receptor modulator, from preclinical data based on pharmacokinetic–pharmacodynamic modeling
    T. Ohno, Chihiro Hasegawa, S. Nakade, Junsaku Kitagawa, Naoki Honda, Mikio Ogawa · 2010 · Biopharmaceutics & drug disposition
34. Prediction of human hepatic clearance using an in vitro plated hepatocyte clearance model.
    P. Chao, J. Barminko, Eric I. Novik, Yi Han, T. Maguire, K.-C. Cheng · 2009 · Drug Metabolism Letters
35. Dealing with Time-Dependent Pharmacokinetics during the Early Clinical Development of a New Leukotriene B4 Synthesis Inhibitor
    Iñaki F. Trocóniz, Ilonka Zsolt, Marı́a J. Garrido, Marta Valle, Rosa María Antonijoan, Manel J. Barbanoj · 2006 · Pharmaceutical Research
36. The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions
    K. Sandy Pang, Hao Peng, Keumhan Noh · 2020 · Pharmaceutics
37. Pharmacokinetics and Metabolism of 4‐O‐Methylhonokiol in Rats
    H. Yu, S. Oh, J. Ryu, J. Kang, J. Hong, Jae-Kyung Jung, S. Han, Seung-Yong Seo, Young Heui Kim, Song-Kyu Park et al. · 2014 · Phytotherapy Research
38. Binding of acellular, native and cross-linked human hemoglobins to haptoglobin: enhanced distribution and clearance in the rat.
    N. Ship, A. Toprak, Roseanna P Lai, E. Tseng, R. Kluger, K. Pang · 2005 · American Journal of Physiology - Gastrointestinal and Liver Physiology
39. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: Comparison among well-stirred, parallel-tube, distributed and dispersion models
    Takahito Yamamoto, H. Itoga, Y. Kohno, K. Nagata, Y. Yamazoe · 2005 · Xenobiotica; the fate of foreign compounds in biological systems
40. Constant-rate infusion of nicotine and cotinine. I. A physiological pharmacokinetic analysis of the cotinine disposition, and effects on clearance and distribution in the rat
    J. Gabrielsson, Ulf Boniesson · 1987 · Journal of pharmacokinetics and biopharmaceutics
41. Pharmacokinetics modeling in drug delivery
    Kuldeep Rajpoot, R. Tekade, Mukesh C. Sharma, M. Safavi, M. Tekade · 2021 · Biopharmaceutics and Pharmacokinetics Considerations
42. Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model
    Toshiaki Tsuchitani, Atsuko Tomaru, Yasunori Aoki, Naoki Ishiguro, Yasuhiro Tsuda, Yuichi Sugiyama · 2024 · CPT: Pharmacometrics & Systems Pharmacology
43. Application of Physiologically Based Pharmacokinetic Modeling in Preclinical Studies: A Feasible Strategy to Practice the Principles of 3Rs
    Yawen Yuan, Qingfeng He, Shunguo Zhang, Min Li, Zhijia Tang, Xiao Zhu, Zheng Jiao, Weimin Cai, Xiaoqiang Xiang · 2022 · Frontiers in Pharmacology
44. Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor
    N. Rioux, K. Duncan, R. Lantz, Xiu-Sheng Miao, Elayne Chan-Penebre, M. Moyer, M. Munchhof, R. Copeland, R. Chesworth, N. Waters · 2016 · Xenobiotica; the fate of foreign compounds in biological systems
45. Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 2. Effect of pharmacological agents, retrograde perfusions, and enzyme inhibition on evans blue, sucrose, water, and taurocholate
    Michael Stephen Roberts, Sharon P Fraser, Andrew Wagner, Lyndsay McLeod · 1990 · Journal of Pharmacokinetics and Biopharmaceutics
46. A Critical Review on the Pharmacodynamics and Pharmacokinetics of Non-steroidal Anti-inflammatory Drugs and Opioid Drugs Used in Reptiles
    A. Ting, Vanessa S. Y. Tay, H. T. Chng, Shang-Zhe Xie · 2022 · Veterinary and Animal Science
47. Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment
    M. Kosloski, Haoyu Wang, D. Pugatch, F. Mensa, E. Gane, E. Lawitz, T. Marbury, R. Preston, J. Kort, Wei Liu · 2018 · European Journal of Clinical Pharmacology
48. Pharmacokinetics of pericyte involvement in small-molecular drug transport across the blood-brain barrier
    Nebojsa Mihajlica, Christer Betsholtz, Margareta Hammarlund‐Udenaes · 2018 · European Journal of Pharmaceutical Sciences
49. A physiologically-based flow network model for hepatic drug elimination II: variable lattice lobule models
    V. Rezania, Rebecca M. Marsh, D. Coombe, J. Tuszynski · 2013 · Theoretical Biology and Medical Modelling
50. Impact of nonlinear midazolam pharmacokinetics on the magnitude of the midazolam-ketoconazole interaction in rats
    Ragini Vuppugalla, Yueping Zhang, Shu Y. Chang, A. David Rodrigues, Punit H. Marathe · 2012 · Xenobiotica
51. A cautionary note on implications of the well‐mixed compartment assumption as applied to mass balance models of chemical fate in flowing systems
    C. Warren, D. Mackay, Eva Webster, J. Arnot · 2009 · Environmental Toxicology and Chemistry
52. Availability predictions by hepatic elimination models for Michaelis-Menten kinetics
    Michael Stephen Roberts, John D. Donaldson, David R. Jackett · 1989 · Journal of Pharmacokinetics and Biopharmaceutics
53. Effect of plasma protein binding on elimination of taurocholate by isolated perfused rat liver: Comparison of venous equilibrium, undistributed and distributed sinusoidal, and dispersion models
    Robert H. Smallwood, Denis J. Morgan, George W. Mihaly, D B Jones, Richard A. Smallwood · 1988 · Journal of Pharmacokinetics and Biopharmaceutics
54. In Vitro and In Silico ADME Prediction
    Angela Effinger, Caitríona M. O’Driscoll, Mark S. McAllister, Nikoletta Fotaki · 2018 · Springer eBooks
55. Pharmacokinetic Modeling of Absorption Behavior of 9-Aminocamptothecin (9-AC) Released from Colon-specific HPMA Copolymer–9-AC Conjugate in Rats
    Song-Qi Gao, Yongen Sun, Pavla Kopečková, C. Matthew Peterson, Jindŕich Kopec̆ek · 2007 · Pharmaceutical Research
56. Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
    Douglas L. Orsi, S. Ferrara, S. Siegel, A. Friberg, L. Bouché, E. Pook, P. Lienau, Joseph P. Bluck, C. Lemke, Gizem Akçay et al. · 2022 · Bioorganic & Medicinal Chemistry
57. Assessment of the Kochak-Benet Equation for Hepatic Clearance for the Parallel-Tube Model: Relevance of Classic Clearance Concepts in PK and PBPK
    W. Jusko, Xiao-Nan Li · 2021 · AAPS Journal
58. In Defense of Current Concepts and Applications of Clearance in Drug Development and Therapeutics
    M. Rowland, M. Roberts, K. Pang · 2021 · Drug Metabolism And Disposition
59. Towards human ex vivo organ perfusion models to elucidate drug pharmacokinetics in health and disease
    Lianne J. Stevens, Joanne M. Donkers, Jeroen Dubbeld, Wouter H. J. Vaes, Catherijne A. J. Knibbe, Ian P.J. Alwayn, Evita van de Steeg · 2020 · Drug Metabolism Reviews
60. Strategies to optimize drug half-life in lead candidate identification
    F. Broccatelli, Cornelis E. C. A. Hop, M. Wright · 2019 · Expert Opinion on Drug Discovery
61. Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease
    James J. Beaudoin, Jacqueline B. Tiley, Yanguang Cao, Katsuhiko Mizuno, Sharin E. Roth, William J. Brock, Kim L. R. Brouwer · 2018 · Drug Metabolism and Disposition
62. Population pharmacokinetics of NNZ‐2566 in healthy subjects
    S. Oosterholt, J. Horrigan, Nancy E. Jones, L. Glass, O. Della Pasqua · 2017 · European Journal of Pharmaceutical Sciences
63. A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions
    Mohammed H. Cherkaoui‐Rbati, Stuart W. Paine, Peter Littlewood, Cyril Rauch · 2017 · PLoS ONE
64. Metabolic Switching of BILR 355 in the Presence of Ritonavir. I. Identifying an Unexpected Disproportionate Human Metabolite
    Yongmei Li, W. G. Lai, Andrea Whitcher-Johnstone, C. A. Busacca, Magnus C. Eriksson, Jon C. Lorenz, D. Tweedie · 2012 · Drug Metabolism And Disposition
65. Application of the Dispersion Model for Description of the Outflow Dilution Profiles of Noneliminated Reference Indicators in Rat Liver Perfusion Studies
    Andreas Schwab, Wanping Geng, K. Sandy Pang · 1998 · Journal of Pharmacokinetics and Biopharmaceutics
66. Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism
    G. M. Rubin, J. Waschek, S. Pond, D. Effeney, T. Tozer · 1987 · Journal of pharmacokinetics and biopharmaceutics
67. Challenges and Opportunities for In Vitro–In Vivo Extrapolation of Aldehyde Oxidase-Mediated Clearance: Toward a Roadmap for Quantitative Translation
    N. Izat, Jayaprakasam Bolleddula, Armina Abbasi, Lionel Cheruzel, Robert S. Jones, Darren Moss, Fátima Ortega-Muro, Yannick Parmentier, Vincent C. Peterkin, Dan-Dan Tian et al. · 2023 · Drug Metabolism And Disposition
68. The impact of desorption kinetics from albumin on hepatic extraction efficiency and hepatic clearance: a model study
    Sophia Krause, K. Goss · 2018 · Archives of Toxicology
69. Functional Integrity of the Chimeric (Humanized) Mouse Liver: Enzyme Zonation, Physiologic Spaces, and Hepatic Enzymes and Transporters
    E. Chow, Jason Z. Ya Wang, H. Quach, Hui Tang, D. C. Evans, Albert P. Li, José M. Silva, K. Pang · 2016 · Drug Metabolism And Disposition
70. Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions.
    K. Iga · 2015 · Journal of Pharmacy and Science
71. A Pharmacokinetic Model for Quantifying the Effect of Vascular Permeability on the Choice of Drug Carrier: A Framework for Personalized Nanomedicine
    Ameya R. Kirtane, Ronald A. Siegel, Jayanth Panyam · 2015 · Journal of Pharmaceutical Sciences
72. Hepatocellular Necrosis, Fibrosis and Microsomal Activity Determine the Hepatic Pharmacokinetics of Basic Drugs in Right-Heart-Failure-Induced Liver Damage
    Peng Li, T. Robertson, Qian Zhang, L. Fletcher, Darrell H. G. Crawford, M. Weiss, M. Roberts · 2012 · Pharmaceutical Research
73. Hepatic Impairment and the Differential Effects on Drug Clearance Mechanisms: Analysis of Pharmacokinetic Changes in Disease State
    Lloyd Wei Tat Tang, M. Varma · 2025 · Clinical pharmacology and therapy
74. Identification of esterase involved in the metabolism of two corticosteroid soft drugs
    A. Samir, N. Bodor, T. Imai · 2017 · Biochemical Pharmacology
75. Pharmacokinetics and metabolism of AMG 232, a novel orally bioavailable inhibitor of the MDM2–p53 interaction, in rats, dogs and monkeys:in vitro–in vivocorrelation
    Qiuping Ye, Min Jiang, Wotang T. Huang, Yun Ling, Steven H. Olson, Daqing Sun, Guifen Xu, Xuelei Yan, Bradley K. Wong, Lixia Jin · 2015 · Xenobiotica
76. Physiologically based pharmacokinetic modeling for assessing the clinical drug–drug interaction of alisporivir
    Binfeng Xia, Avantika Barve, Tycho Heimbach, Tao Zhang, Helen Gu, Lai Wang, Heidi J. Einolf, Natalya Alexander, Imad H. Hanna, June Ke et al. · 2014 · European Journal of Pharmaceutical Sciences
77. Prediction of a potentially effective dose in humans for BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically‐based pharmacokinetic modelling
    Olaf Weber, Stefan Willmann, Hilmar Bischoff, Volkhart Li, Alexandros Vakalopoulos, Klemens Lustig, Frank‐Thorsten Hafner, Roland Heinig, Carsten Schmeck, Klaus Buehner · 2011 · British Journal of Clinical Pharmacology
78. In vitro metabolism of KBH-A40, a novel δ-lactam-based histone deacetylase (HDAC) inhibitor, in human liver microsomes and serum
    Hwan-Mook Kim, Soo Jin Oh, Song-Kyu Park, G. Han, Ki-suk Kim, Kyung-Jung Lee, J. Kang, M. Nam, Kiho Lee · 2008
79. Prediction of human clearance (CL) and volume of distribution (VD)
    Jörg Keldenich · 2004 · Drug Discovery Today Technologies
80. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics
    Gerald M. Rubin, Thomas N. Tozer · 1984 · Journal of Pharmacokinetics and Biopharmaceutics
81. Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier
    Laura E. Russell, Jaydeep Yadav, B. Maldonato, Huan-Chieh Chien, Ling Zou, Ana G Vergara, Erick G Villavicencio · 2024 · Drug metabolism reviews (Softcover ed.)
82. Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration
    Jieon Lee, Yuching Yang, Xinyuan Zhang, Jianghong Fan, Manuela Grimstein, Hao‐Jie Zhu, Yaning Wang · 2021 · The Journal of Clinical Pharmacology
83. Prediction of Metabolite‐to‐Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model
    Ernesto Callegari, M. Varma, R. Obach · 2019 · Clinical and Translational Science
84. Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy
    Philippe Bernard Pierrillas, Émilie Hénin, Kathryn Ball, Julien R. Ogier, Magali Amiel, Laurence Kraus‐Berthier, Marylore Chenel, François Bouzom, Michel M. Tod · 2019 · Drug Metabolism and Disposition
85. A new descriptor via bio‐mimetic chromatography and modeling for the blood brain barrier (Part II)
    Maria G. Kouskoura, Aikaterini I. Piteni, C. Markopoulou · 2019 · Journal of Pharmaceutical and Biomedical Analysis
86. Discussions on the hepatic well-stirred model: Re-derivation from the dispersion model and re-analysis of the lidocaine data
    Jin Dong, Miki Susanto Park · 2018 · European Journal of Pharmaceutical Sciences
87. Synthesis, biological evaluation, and metabolic stability of chlorogenic acid derivatives possessing thiazole as potent inhibitors of α-MSH-stimulated melanogenesis.
    Hyeju Jo, Yuanyuan Zhou, M. Viji, Min-Ho Choi, Jae Young Lim, Jaeuk Sim, J. Rhee, Youngsoo Kim, Seung-Yong Seo, W. Kim et al. · 2017 · Bioorganic & Medicinal Chemistry Letters
88. Inhibition of glucuronidation and oxidative metabolism of buprenorphine using GRAS compounds or dietary constituents/supplements: in vitro proof of concept
    A. Rostami-Hodjegan, I. Tamai, K. Pang, Neha Maharao, Anand Joshi, P. Gerk · 2017 · Biopharmaceutics & drug disposition
89. Deriving an explicit hepatic clearance equation accounting for plasma protein binding and hepatocellular uptake
    Miyoung Yoon, Harvey J. Clewell III M.A., Melvin E. Andersen · 2012 · Toxicology in Vitro
90. Evaluation of the novel in vitro systems for hepatic drug clearance and assessment of their predictive utility
    James Brian. Houston, K Rowland‐Yeo, Ugo Zanelli · 2012 · Toxicology in Vitro
91. Interindividual pharmacokinetics variability of the alpha(4)beta(1) integrin antagonist, 4-[1-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), in beagles is associated with albumin genetic polymorphisms.
    Takashi Ito, Masayuki Takahashi, K. Sudo, Y. Sugiyama · 2009 · Journal of Pharmacy and Science
92. The Role of Sulfotransferases (SULTs) and UDP-Glucuronosyltransferases (UGTs) in Human Drug Clearance and Bioactivation
    Michael W.H. Coughtrie, Michael Fisher · 2003 · Informa Healthcare eBooks
93. A theoretical examination of the effects of gut wall metabolism, hepatic elimination, and enterohepatic recycling on estimates of bioavailability and of hepatic blood flow
    K. Pang, J. Gillette · 1978 · Journal of pharmacokinetics and biopharmaceutics
94. In vitro metabolism of CP-122,721 ((2S,3S)-2-phenyl-3-[(5-trifluoromethoxy-2-methoxy)benzylamino]piperidine), a non-peptide antagonist of the substance P receptor.
    R. Obach, Jeannine M. Margolis, M. Logman · 2007 · Drug Metabolism and Pharmacokinetics
95. Theoretical Considerations for Direct Translation of Unbound Liver-to-Plasma Partition Coefficient from In Vitro to In Vivo
    Zhenhong Li, Li Di, Tristan S. Maurer · 2019 · The AAPS Journal
96. Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomes
    Marike Visser, M. J. Zaya, C. Locuson, D. Boothe, D. A. Merritt · 2019 · Xenobiotica; the fate of foreign compounds in biological systems
97. Evaluation of hypothermia on thein vitrometabolism and binding andin vivodisposition of midazolam in rats
    Hirotaka Miyamoto, Satoshi Matsueda, Akihiro Moritsuka, Kenta Shimokawa, Haruna Hirata, Mikiro Nakashima, Hitoshi Sasaki, Shintaro Fumoto, Koyo Nishida · 2015 · Biopharmaceutics & Drug Disposition
98. Metabolic characterization of meso-dihydroguaiaretic acid in liver microsomes and in mice.
    Jang Su Jeon, S. Oh, Ji-Yoon Lee, C. Ryu, Young-mi Kim, Byung Hoon Lee, S. K. Kim · 2015 · Food and Chemical Toxicology
99. Computational approaches to analyse and predict small molecule transport and distribution at cellular and subcellular levels
    Kyoung Ah Min, Xinyuan Zhang, Jing‐yu Yu, Gus R. Rosania · 2013 · Biopharmaceutics & Drug Disposition
100. Pharmacokinetics of clonidine in the rat and cat
     L. Paalzow, P. Edlund · 1979 · Journal of pharmacokinetics and biopharmaceutics